

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

# **REGULATORY FORMS**

# FORMS RELATING TO LISTING

# FORM G

### GEM

# COMPANY INFORMATION SHEET

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

Company name:

A. General

# Shenzhen Neptunus Interlong Bio-technique Company Limited (深圳市海王英特龍生物技術股份有限公司)

| Stock code         | 8329 |
|--------------------|------|
| (ordinary shares): |      |

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on GEM of The Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the Exchange's website on the internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of <u>21 February 2024</u>

| The People's Republic of China |
|--------------------------------|
| 12 September 2005              |
| First Shanghai Capital Limited |
|                                |

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Names of directors: (please distinguish the status of the directors - Executive, Non-Executive or Independent Non-Executive)

Executive Directors:-Zhang Feng Huang Jian Bo Zhang Xiao Guang

Non-Executive Directors:-Zhang Yi Fei Yu Lin Jin Rui

Independent Non-Executive Directors:-Yick Wing Fat, Simon Poon Ka Yeung Zhang Jian Zhou

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

| Name(s) of substantial shareholder(s):<br>(as such term is defined in rule 1.01 of<br>the GEM Listing Rules) and their<br>respective interests in the ordinary<br>shares and other securities of the<br>Company | Name of<br>Shareholders   | Number of<br>Shares                | Capacity                                 | Approximate<br>percentage of<br>shareholding |
|---|---|------------------------------------|--|--|
|   | Shenzhen<br>Neptunus Bio-<br>engineering  | 1,181,000,000<br><i>(Note(a))</i>  | Beneficial<br>owner                      | 70.38%                                       |
|   | Co., Ltd.<br>("Neptunus<br>Bio-<br>engineering")  | 52,464,500<br>(Note(a))            | Interest in<br>controlled<br>corporation | 3.13%  |
|   | Shenzhen<br>Neptunus<br>Group<br>Company<br>Limited<br>(" <b>Neptunus</b><br><b>Group</b> ")  | 1,233,464,500<br>(Note (b))        | Interest in<br>controlled<br>corporation | 73.51%                                       |
|   | Shenzhen<br>Neptunus<br>Holding Group<br>Company<br>Limited<br>(" <b>Neptunus</b><br><b>Holding</b> ")<br>(Previously<br>known as<br>"Shenzhen<br>Yinhetong<br>Investment<br>Company<br>Limited") | 1,233,464,500<br><i>(Note (c))</i> | Interest in<br>controlled<br>corporation | 73.51%                                       |
|   | Zhang Si Min  | 1,233,464,500<br>(Note (d))        | Interest in<br>controlled<br>corporation | 73.51%                                       |

Notes:

- (a) As at the date of updating this information sheet, of 1,233,464,500 domestic shares ("Domestic Shares") of the Company being interested by Neptunus Bio-engineering, 1,181,000,000 domestic shares were directly held and 52,464,500 domestic shares were held through Shenzhen Neptunus Oriental Investment Company Limited which was wholly owned by Neptunus Bio-engineering.
- (b) As at the date of updating this information sheet, Neptunus Group was beneficially interested in approximately 44.22% of the entire issued share capital of Neptunus Bio-engineering.

#### **THE STOCK EXCHANGE OF HONG KONG LIMITED** (A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

(c) As at the date of updating this information sheet, Neptunus Holding was beneficially interested in approximately 59.68% of the entire issued share capital of Neptunus Group, which in turn was beneficially interested in approximately 44.22% of the entire issued share capital of Neptunus Bio-engineering.

(d) As at the date of updating this information sheet, Mr. Zhang Si Min ("Mr. Zhang") was deemed to be interested in 1,233,464,500 Domestic Shares held by Neptunus Bio-engineering, as Mr. Zhang was beneficially interested in 70% of the entire issued share capital of Neptunus Holding and the entire issued share capital of Shenzhen Haihe Investment and Development Company Limited, which in turn was beneficially interested in approximately 59.68% and 20% of the entire issued share capital of Neptunus Group respectively. Neptunus Group was beneficially interested in approximately 44.22% of the entire issued share capital of Neptunus Bio-engineering.

| Name(s) of company(ies) listed on GEM<br>or the Main Board of the Stock<br>Exchange within the same group as the<br>Company: | N/A   |
|--|---|
| Financial year end date:   | 31 December   |
| Registered address:  | Suite 1702, Neptunus Yinhe Technology Mansion, 1 Keji<br>Middle 3rd Road, Maling Community, Yuehai Sub-district,<br>Nanshan District, Shenzhen, The People's Republic of<br>China |
| Head office and principal place of business:   | 43/F, One Taikoo Place, 979 King's Road, Quarry Bay, Hong<br>Kong   |
| Web-site address (if applicable):  | www.interlong.com   |
| Share registrar:   | Tricor Investor Services Limited  |
| Auditors:  | Grant Thornton Hong Kong Limited  |

### B. Business activities

(Please insert here a brief description of the business activities undertaken by the Company and its subsidiaries.)

The Company and its subsidiaries principally engage in the research and development, manufacturing and selling of medicines and medical devices, and the purchase and sales of medicines and healthcare food products.

### C. Ordinary shares

| Number of ordinary shares in issue:    | 1,252,000,000 Domestic Shares and 426,000,000 H Shares |
|--|--|
| Par value of ordinary shares in issue: | RMB 0.10   |

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

| Board lot size (in number of shares):   | 10,000 H Shares |
|---|-----------------|
| Name of other stock exchange(s)<br>on which ordinary shares are also<br>listed:                               | N/A             |
| D. Warrants   |                 |
| Stock code:   | N/A             |
| Board lot size:   | N/A             |
| Expiry date:  | N/A             |
| Exercise price:   | N/A             |
| Conversion ratio:<br>(Not applicable if the warrant is<br>denominated in dollar value of<br>conversion right) | N/A             |
| No. of warrants outstanding:  | N/A             |
| No. of shares falling to be issued upon the exercise of outstanding warrants:                                 | N/A             |

## E. Other securities

Details of any other securities in issue.

(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

N/A

#### Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet ("the Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

### **THE STOCK EXCHANGE OF HONG KONG LIMITED** (A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Submitted by:

(Name)

Title:

(Director, secretary or other duly authorised officer)

# NOTE

Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the Exchange's website a revised information sheet as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.